Evidence map›Paper›PMID 32354888›Full record

ArticleIn vivo (Athens, Greece)

Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP

Yuki Katsuya, Kentaro Miyake, Takashi Higuchi, Hiromichi Oshiro, Norihiko Sugisawa, Shree Ram Singh, Yasushi Goto, Ming Zhao, Robert M Hoffman

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Dose Reduction ofCancer diagnosis & prognosis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuki KatsuyaAntiCancer, Inc., San Diego, CA, U.S.A.
Kentaro MiyakeAntiCancer, Inc., San Diego, CA, U.S.A.
Takashi HiguchiAntiCancer, Inc., San Diego, CA, U.S.A.
Hiromichi OshiroAntiCancer, Inc., San Diego, CA, U.S.A.
Norihiko SugisawaAntiCancer, Inc., San Diego, CA, U.S.A.
Shree Ram SinghBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center, Tokyo, Japan.
Ming ZhaoAntiCancer, Inc., San Diego, CA, U.S.A.
Robert M HoffmanAntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov.
University of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimBrain metastases are found in approximately 30% of patients with epidermal-growth-factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We compared the efficacy of two EGFR-tyrosine kinase inhibitors (TKIs), erlotinib and osimertinib on a PC-9-GFP EGFR mutant NSCLC growing in the brain of nude mice. MATERIALS AND

methodsThe brain metastasis models were randomized into five groups and treated for 15 days: Control; 5 mg/kg erlotinib; 50 mg/kg erlotinib; 0.5 mg/kg osimertinib; 5 mg/kg osimertinib. Tumor volume was evaluated by non-invasive fluorescence imaging.

resultsOnly 5 mg/kg osimertinib, a low-dose compared to the clinically-equivalent dose, showed significant tumor regression compared to the control.

conclusionThis study strongly supports the high activity of osimertinib for intracranial lesions of EGFR-mutant NSCLC.

Indexed as

AcrylamidesAniline CompoundsAnimalsBrain NeoplasmsCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalDrug SynergismDrug Therapy, CombinationErbB ReceptorsErlotinib HydrochlorideFemaleGenes, ReporterIndolesLung NeoplasmsMaleAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideIndolesosimertinibProtein Kinase InhibitorsPyrimidinesErlotinibnon-small cell lung cancernude miceosimertinibPC-9-GFP

Identifiers

PMID32354888
PMCPMC7279826
OpenAlexW3021901023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.